Cullinan Therapeutics, Inc. (CGEM)
NASDAQ: CGEM · Real-Time Price · USD
13.70
+0.72 (5.55%)
At close: Jun 12, 2026, 4:00 PM EDT
13.43
-0.27 (-1.97%)
After-hours: Jun 12, 2026, 7:43 PM EDT
Cullinan Therapeutics Employees
Cullinan Therapeutics had 109 employees as of December 31, 2025. The number of employees decreased by 2 or -1.80% compared to the previous year.
Employees
109
Change (1Y)
-2
Growth (1Y)
-1.80%
Revenue / Employee
n/a
Profits / Employee
-$2,027,881
Market Cap
841.98M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 109 | -2 | -1.80% | 109 | 0 |
| Dec 31, 2024 | 111 | 26 | 30.59% | 111 | 0 |
| Dec 31, 2023 | 85 | 23 | 37.10% | 85 | 0 |
| Dec 31, 2022 | 62 | 31 | 100.00% | 62 | 0 |
| Mar 31, 2022 | 37 | 13 | 54.17% | 37 | 0 |
| Dec 31, 2021 | 31 | 7 | 29.17% | 31 | 0 |
| Sep 30, 2021 | 33 | 15 | 83.33% | 33 | 0 |
| Jun 30, 2021 | 28 | 11 | 64.71% | 28 | 0 |
| Mar 31, 2021 | 24 | 7 | 41.18% | 24 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Phathom Pharmaceuticals | 371 |
| Kura Oncology | 260 |
| Sana Biotechnology | 142 |
| Olema Pharmaceuticals | 137 |
| Janux Therapeutics | 108 |
| ORIC Pharmaceuticals | 104 |
| Theravance Biopharma | 90 |
| Lexicon Pharmaceuticals | 81 |
CGEM News
- 4 days ago - Cullinan Therapeutics price target raised to $46 from $33 at Clear Street - TheFly
- 4 days ago - Cullinan Therapeutics Transcript: Immunology Day 2026 - Transcripts
- 4 days ago - Cullinan Therapeutics Slides: FY 2026 - Filings
- 4 days ago - Cullinan Therapeutics Press release: FY 2026 - Filings
- 4 days ago - Cullinan Therapeutics reports CLN-978, velinotamig data - TheFly
- 4 days ago - Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases - GlobeNewsWire
- 7 days ago - Cullinan Therapeutics presents clinical data for CLN-978 - TheFly
- 19 days ago - Cullinan to host Immunology Day event, announce data for CLN-978, Velinotamig - TheFly